JP2014525933A5 - - Google Patents

Download PDF

Info

Publication number
JP2014525933A5
JP2014525933A5 JP2014526184A JP2014526184A JP2014525933A5 JP 2014525933 A5 JP2014525933 A5 JP 2014525933A5 JP 2014526184 A JP2014526184 A JP 2014526184A JP 2014526184 A JP2014526184 A JP 2014526184A JP 2014525933 A5 JP2014525933 A5 JP 2014525933A5
Authority
JP
Japan
Prior art keywords
polypeptide
spa
binding
pharmaceutical composition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014526184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525933A (ja
JP6317670B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/050991 external-priority patent/WO2013025834A2/en
Publication of JP2014525933A publication Critical patent/JP2014525933A/ja
Publication of JP2014525933A5 publication Critical patent/JP2014525933A5/ja
Application granted granted Critical
Publication of JP6317670B2 publication Critical patent/JP6317670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014526184A 2011-08-15 2012-08-15 ブドウ球菌プロテインａに対する抗体に関連した組成物および方法 Active JP6317670B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161523751P 2011-08-15 2011-08-15
US61/523,751 2011-08-15
US201261615083P 2012-03-23 2012-03-23
US61/615,083 2012-03-23
US201261618417P 2012-03-30 2012-03-30
US61/618,417 2012-03-30
US201261674135P 2012-07-20 2012-07-20
US61/674,135 2012-07-20
PCT/US2012/050991 WO2013025834A2 (en) 2011-08-15 2012-08-15 Compositions and methods related to antibodies to staphylococcal protein a

Publications (3)

Publication Number Publication Date
JP2014525933A JP2014525933A (ja) 2014-10-02
JP2014525933A5 true JP2014525933A5 (enExample) 2015-09-10
JP6317670B2 JP6317670B2 (ja) 2018-04-25

Family

ID=47715689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014526184A Active JP6317670B2 (ja) 2011-08-15 2012-08-15 ブドウ球菌プロテインａに対する抗体に関連した組成物および方法

Country Status (8)

Country Link
US (2) US9556281B2 (enExample)
EP (1) EP2744517B1 (enExample)
JP (1) JP6317670B2 (enExample)
CN (1) CN103906535B (enExample)
AU (1) AU2012296576B2 (enExample)
BR (1) BR112014003315A2 (enExample)
CA (1) CA2845259A1 (enExample)
WO (1) WO2013025834A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2793944B1 (en) 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2844275B1 (en) * 2012-04-26 2020-05-13 University of Chicago Staphylococcal coagulase antigens and methods of their use
CA2890427C (en) * 2012-11-06 2022-05-31 Medimmune, Llc Antibodies to s. aureus surface determinants
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
US20160244511A1 (en) * 2013-10-17 2016-08-25 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
WO2015187779A1 (en) * 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
JP6813258B2 (ja) 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス 化学療法の組み合わせ
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
JP6936784B2 (ja) 2015-03-30 2021-09-22 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法
EP3283513A1 (en) * 2015-04-17 2018-02-21 ARSANIS Biosciences GmbH Antibody directed against immunoglobulin-binding proteins of s. aureus
CA2978855A1 (en) 2015-04-17 2016-10-20 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
EP3383412A4 (en) 2015-12-02 2019-06-05 Stcube, Inc. SPECIFIC ANTIBODIES TO GLYCOSED PD-1 AND METHOD OF USE THEREOF
KR20180130541A (ko) 2016-03-29 2018-12-07 주식회사 에스티큐브앤컴퍼니 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
JP7241541B2 (ja) 2016-03-29 2023-03-17 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ－ｌ１に特異的な二重機能抗体およびその使用方法
CN109715666B (zh) 2016-07-20 2023-02-21 斯特库比股份有限公司 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112020015999A2 (pt) * 2018-04-06 2020-12-15 Dana-Farber Cancer Institute, Inc. Kir3dl3 como um receptor de hhla2, anticorpos anti-hhla2 e usos dos mesmos
CN110655577A (zh) * 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
CN110078832B (zh) * 2019-04-18 2021-12-14 江南大学 一类基于ZZ domain的二抗及其制备方法和应用
EP4028426A4 (en) * 2019-09-13 2023-10-11 The University of Chicago METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS
AU2020387401A1 (en) * 2019-11-18 2022-05-26 Board Of Regents, The University Of Texas System Anti-B7-H3 monoclonal antibody and methods of use thereof
CN111072776A (zh) * 2019-12-26 2020-04-28 成都欧林生物科技股份有限公司 抗SpA5蛋白的单克隆抗体及其应用和包含其的试剂盒
CN114163524B (zh) * 2021-12-06 2023-08-11 郑州伊美诺生物技术有限公司 抗体及其在a蛋白检测中的应用
PL246485B1 (pl) 2022-08-25 2025-02-03 Univ Jagiellonski Sposób i kompozycja diagnostyczna do wykrywania mastitis wywołanego przez E. coli, S. uberis, S. agalactiae lub S. aureus
WO2024086684A2 (en) * 2022-10-19 2024-04-25 Ibio, Inc. Chemokine receptor 8 (ccr8) antibodies
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒
CN118580347B (zh) * 2024-05-13 2025-02-07 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌蛋白a的单克隆抗体及其应用

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4338298A (en) 1980-04-04 1982-07-06 Endowment And Research Foundation At Montana State University Vaccine for passive immunization against enteric colibacillosis and method of use
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
NZ251621A (en) 1992-03-26 1996-04-26 Microcarb Inc Polyclonal antibodies to shiga-like toxins
DE69334225D1 (de) 1992-07-07 2008-07-31 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
EP0652965A1 (en) 1992-07-27 1995-05-17 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
US6048616A (en) 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US6770278B1 (en) 1994-12-02 2004-08-03 Central Biomedia, Inc. Methods of making and using immunoglobulin (Ig) compositions
US5548066A (en) 1994-12-02 1996-08-20 Central Biomedia, Inc. Failure of passive transfer immune serum and method of making same
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
JPH11514870A (ja) 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
WO1997043314A2 (en) 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
GB9806762D0 (en) 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
AU758019B2 (en) 1998-07-10 2003-03-13 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine
CA2341177A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6635473B1 (en) 1998-08-31 2003-10-21 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
DK1121135T3 (da) 1998-09-14 2009-03-23 Nabi Biopharmaceuticals Præparater af beta-glucaner og specifikke immunglobuliner
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
AU4701200A (en) 1999-05-07 2000-11-21 Quantum Dot Corporation A method of detecting an analyte using semiconductor nanocrystals
WO2000069457A1 (en) * 1999-05-15 2000-11-23 University Of California, San Diego Protein a based binding domains with desirable activities
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
AU1486102A (en) 2000-11-07 2002-05-21 Immunovaccine Technologies Inc Vaccines with enhanced immune response and methods for their preparation
WO2002074324A1 (en) 2001-03-15 2002-09-26 The Texas A & M University System Collagen-binding adhesin from staphylococcus epidermidis and method of use
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
DK1745075T3 (da) * 2004-04-21 2013-06-24 Brigham & Womens Hospital Poly-n-acetylglucosamin (pnag/dpnag)-bindende peptider og fremgangsmåder til anvendelse deraf
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
EP1814918A1 (en) 2004-10-29 2007-08-08 Elusys Therapeutics, Inc. Use of cr1-binding molecules in clearance and induction of immune responses
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
WO2008140487A2 (en) * 2006-11-14 2008-11-20 Elusys Therapeutics, Inc. Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US20100047252A1 (en) 2006-11-22 2010-02-25 3M Innovative Properties Company Antibody with protein a selectivity
US8389682B2 (en) * 2007-01-16 2013-03-05 Trustees Of Columbia University In The City Of New York Inhibiting Staphylococcus epidermidis infections
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
CN101952729A (zh) 2008-02-20 2011-01-19 3M创新有限公司 利用全细胞捕获和atp分析进行样品细菌分析的方法
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
SMT202000246T1 (it) * 2009-04-03 2020-07-08 Univ Chicago Composizioni e metodi relativi a varianti della proteina a (spa)
BR112013000097B1 (pt) 2010-07-02 2022-02-01 The University Of Chicago Polipeptídeo imunogênico isolado, composição imunogênica e seu uso
US10319609B2 (en) 2017-06-21 2019-06-11 International Business Machines Corporation Adhesive-bonded thermal interface structures

Similar Documents

Publication Publication Date Title
JP2014525933A5 (enExample)
JP6672221B2 (ja) 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症を治療および予防するための組成物および方法
CN101379085B (zh) Il-12/p40结合蛋白
JP6845016B2 (ja) 多細菌性感染の治療
CN109071664B (zh) 新型抗-SIRPa抗体及其治疗应用
ES2685607T3 (es) Usos y composiciones para el tratamiento de la hidradenitis supurativa (HS)
JP2015515492A5 (enExample)
JP2016508153A5 (enExample)
JP2016507555A5 (enExample)
JP2019527194A5 (enExample)
JP2018529635A5 (enExample)
CN115785272A (zh) 新型抗-SIRPa抗体及其治疗应用
RU2019140933A (ru) Средства, пути применения и способы лечения
CA3115633A1 (en) Combinations of anti-staphylococcus aureus antibodies
JP2013508292A5 (enExample)
JP2020527152A5 (enExample)
JP2015509960A5 (enExample)
JP2020502219A5 (enExample)
JP2016501877A5 (enExample)
RU2015143696A (ru) МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АНТИТРОМБИНА β
JP2013538573A (ja) 黄色ブドウ球菌特異的なヒト組換えポリクローナル抗体およびその使用
JP2019514343A5 (enExample)
JP2010540660A5 (enExample)
TW202114734A (zh) Il-17拮抗劑治療自身免疫疾病的方法
WO2025218746A1 (en) Methods of treating rheumatoid arthritis